益丰大药房连锁股份有限公司 2025 年第二次临时股东会会议资料 益丰大药房连锁股份有限公司 2025 年第二次临时股东会 会议资料 2025 年 8 月 1 / 47 益丰大药房连锁股份有限公司 2025 年第二次临时股东会会议资料 | | | | 2025 | 年第二次临时股东会会议议程····························································· | 3 | | --- | --- | --- | | 2025 | 年第二次临时股东会会议须知····························································· | 5 | | 2025 | 年第二次临时股东会会议议案····························································· | 6 | | 议案 | 1：关于取消监事会并修订《公司章程》的议案······································ | 6 | | 议案 | 2：关于修订《董事会议事规则》的议案 ...

天眼查商业履历信息显示，益丰大药房连锁股份有限公司，成立于2008年，位于常德市，是一家以从事 卫生为主的企业。企业注册资本121243.2297万人民币，实缴资本12000万人民币。公司法定代表人为高 毅。 通过天眼查大数据分析，益丰大药房连锁股份有限公司共对外投资了33家企业，参与招投标项目1315 次，知识产权方面有商标信息311条，专利信息6条，此外企业还拥有行政许可127个。 来源：金融界 金融界消息 截至2025年8月19日收盘，益丰药房（603939）报收于24.06元，上涨0.8%，换手率0.78%， 成交量9.42万手，成交金额2.27亿元。 资金流向方面，今日主力资金净流入1472.66万元，占比成交额6.49%。其中，超大单净流入1146.64万 元、占成交额5.06%，大单净流入326.03万元、占成交额1.44%，中单净流出流出582.78万元、占成交额 2.57%，小单净流出889.88万元、占成交额3.92%。 益丰药房最新一期业绩显示，截至2025一季报，公司营业总收入60.09亿元、同比增长0.64%，归属净利 润4.49亿元，同比增长10.51%，扣非净利润4.38亿元，同 ...

Market Performance - The pharmaceutical commercial sector increased by 0.67% compared to the previous trading day, with Saily Medical leading the gains [1] - The Shanghai Composite Index closed at 3728.03, up 0.85%, while the Shenzhen Component Index closed at 11835.57, up 1.73% [1] Individual Stock Performance - Saily Medical (603716) closed at 29.87, up 5.14%, with a trading volume of 409,100 shares and a transaction value of 1.187 billion [1] - Yifeng Pharmacy (603939) closed at 23.87, up 2.14%, with a trading volume of 100,900 shares and a transaction value of 239 million [1] - Other notable performers include Yaoyigou (300937) at 30.10 (+2.03%), Laobaixing (603883) at 18.43 (+1.26%), and Haiwang Biological (000078) at 2.69 (+1.13%) [1] Capital Flow Analysis - The pharmaceutical commercial sector experienced a net outflow of 10.8635 million from institutional investors, while retail investors saw a net inflow of 12.0341 million [2] - The overall capital flow indicates a mixed sentiment, with institutional investors withdrawing funds while retail investors increased their positions [2] Detailed Capital Flow for Selected Stocks - Saily Medical had a net outflow of 95.4222 million from institutional investors, while retail investors contributed a net inflow of 45.8725 million [3] - Guoyao Co. (600511) saw a net inflow of 38.7702 million from institutional investors, but a net outflow of 35.7166 million from retail investors [3] - Other stocks like Zhejiang Zhenyuan (000705) and Ruikang Pharmaceutical (002589) also showed varied capital flows, indicating differing investor sentiments across the sector [3]

Group 1 - The board meeting of Yifeng Pharmacy Chain Co., Ltd. was held on August 14, 2025, with all nine directors present and no dissenting votes [1][2] - The board unanimously approved all agenda items during the meeting, indicating strong consensus among the directors [1][2] - The company plans to apply for a bank credit limit for its wholly-owned subsidiary, Hubei Yifeng Pharmacy Chain Co., Ltd., with the credit limit being subject to bank approval and available for revolving use [2] Group 2 - The meeting was convened by Chairman Gao Yi and followed legal and regulatory procedures, ensuring the validity of the resolutions made [1] - The decision to waive the notice period for the board meeting was made due to the urgency of the matters being discussed [1] - The proposal for bank credit will be submitted for shareholder approval in the upcoming meeting [2]

Group 1 - The company held the 14th meeting of the 5th Supervisory Board on August 14, 2025, in Changsha, Hunan Province, with all three supervisors present and voting [1][2][3] - The meeting was convened and chaired by Mr. Chen Bin, the chairman of the Supervisory Board, and all resolutions passed were deemed legal and effective [1][3] - The Supervisory Board approved a proposal for the wholly-owned subsidiary, Hubei Yifeng Pharmacy Chain Co., Ltd., to apply for a bank credit limit, which is subject to bank approval and can be reused within the credit period [2]

Group 1 - The company announced an increase in temporary proposals for the second extraordinary general meeting of shareholders scheduled for August 25, 2025 [1][2] - The proposal to be added is regarding the company's guarantee for a subsidiary's bank credit application, submitted by a major shareholder holding 19.88% of the shares [2][3] - The original notice of the shareholders' meeting remains unchanged aside from the added proposal [2][3] Group 2 - The meeting will take place at 14:30 on August 25, 2025, at the company's logistics park in Changsha, Hunan Province [2][3] - Online voting will be available through the Shanghai Stock Exchange's system on the same day, with specific voting time slots outlined [2][3] - The equity registration date for the shareholders' meeting remains unchanged [3]

Core Viewpoint - Yifeng Pharmacy announced the approval of the proposal to waive the notification period for the 14th meeting of the fifth supervisory board [2] Group 1 - The fifth supervisory board of Yifeng Pharmacy held its 14th meeting on August 14 [2] - The meeting included the review and approval of the proposal regarding the waiver of the notification period [2]

（文章来源：证券日报） 证券日报网讯 8月14日晚间，益丰药房发布公告称，公司第五届董事会第二十次会议审议通过了《关于 豁免第五届董事会第二十次会议通知时限的议案》等。 ...

Group 1 - The core point of the article is that Yifeng Pharmacy announced its total external guarantee amounting to 261,500,000 yuan, which represents 24.38% of the company's most recent audited net assets [2][2][2] - The company confirmed that there are no overdue guarantees as of the announcement date [2][2][2]

| 证券代码：603939 | 证券简称：益丰药房 | 公告编号：2025-073 | | --- | --- | --- | | 债券代码：113682 | 债券简称：益丰转债 | | 益丰大药房连锁股份有限公司 第五届董事会第二十次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 一、 董事会会议召开情况 益丰大药房连锁股份有限公司（以下简称"公司"）于 2025 年 8 月 13 日以 电子邮件方式发出第五届董事会第二十次会议通知，会议于 2025 年 8 月 14 日在 湖南省长沙市金洲大道 68 号益丰医药物流园四楼会议室以现场加通讯方式召开， 应参加表决的董事 9 人，实际参加表决的董事 9 人，公司监事和高级管理人员列 席了会议，本次会议的召集、召开和表决程序符合有关法律、法规和《公司章程》 的规定，会议形成的决议合法有效。 二、 董事会会议审议情况 本次会议由董事长高毅先生召集并主持，采用记名投票方式，审议并通过了 如下议案： 公司为全资子公司湖北益丰大药房连锁有限公司向银行申 ...